Prof. Dr. Meral Beksaç

Makaleler

• 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders , 2025
• A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT , 2026
• Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone , 2026
• Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study , 2026
• [11C]-Methionine PET/CT in evaluation of bone marrow infiltration and usage as a prognostic tool in multiple myeloma , 2026
• Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study , 2026
• Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy , 2026
• Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset , 2025
• A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant , 2025
• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network , 2025
• Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials , 2025
• Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial , 2025
• Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma , 2025
• EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma , 2025
• Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS , 2025
• Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT , 2025
• Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions , 2025
• European Myeloma Network Group review and consensus statement on primary plasma cell leukemia , 2025
• Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT , 2024
• Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network , 2025
• Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial , 2025
• Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods , 2025
• A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma , 2025
• Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic , 2025
• Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel , 2025
• A plain language summary of the ICARIA study, comparing isatuximab–pomalidomide– dexamethasone with pomalidomide– dexamethasone in people with multiple myeloma , 2025
• Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data. , 2025
• Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. , 2025
• Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial. , 2025
• DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients with high-risk cytogenetic features. , 2025
• Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf). , 2025
• Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study. , 2025
• Efficacy and safety outcomes in patients (pts) with renal impairment in the phase 3 DREAMM-7 and DREAMM-8 trials. , 2025
• Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis. , 2025
• Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study , 2025
• Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group , 2025
• A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT , 2025
• Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial , 2025
• VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG) , 2025
• Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial , 2025
• Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma , 2024
• Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma , 2024
• In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT , 2024
• Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases , 2024
• Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation , 2020
• Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG) , 2024
• Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study , 2024
• Transcriptome analysis of beta-catenin-related genes in CD34+ haematopoietic stem and progenitor cells from patients with AML , 2024
• A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma , 2024
• Current Landscape of iPSC Haplobanks , 2024
• A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma , 2024
• Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). , 2024
• Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis , 2024
• Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment , 2024
• In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide , 2024
• Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison , 2024
• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma , 2024
• Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells , 2024
• Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients , 2024
• A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity , 2021
• Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group , 2023
• Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation , 2023
• Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT , 2023
• Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center , 2023
• Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network , 2023
• Werner helicase is required for proliferation and DNA damage repair in multiple myeloma , 2022
• Upfront autologous transplantation still improving outcomes in patients with multiple myeloma , 2023
• Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome , 2023
• Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study , 2023
• HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma , 2023
• An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT , 2023
• A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset , 2023
• Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data , 2023
• Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT , 2023
• Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial , 2023
• Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors , 2021
• A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker , 2016
• Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center , 2018
• Upfront autologous transplantation still improving outcomes in patients with multiple myeloma , 2022
• First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey , 2022
• ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma , 2022
• Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper , 2022
• Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful? , 2022
• When a Monoclonal Gammopathy Is Not Multiple Myeloma , 2022
• Health\u2010related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient\u2010reported outcomes from the APOLLO trial , 2022
• Chronic graft-versus-host disease complicated by membranous glomerulonephritis , 1999
• Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma , 2012
• Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma , 2022
• Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA , 2022
• Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial , 2022
• Manual Versus Automated Volume Reduction of Cord Blood , 2022
• Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT , 2022
• Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT , 2022
• Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis , 2022
• The efficacy and safety of second allogeneic hematopoietic stem cell transplantation. , 2022
• Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia , 2022
• Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies , 2022
• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study , 2022
• Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics , 2022
• Health\u2010related quality of life in patients with\n <scp>light chain<\/scp>\n amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u2009±\u2009daratumumab: Results from the\n <scp>ANDROMEDA<\/scp>\n study , 2022
• Extramedullary disease in multiple myeloma: a systematic literature review , 2022
• Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019 , 2022
• Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease , 2022
• Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study , 2022
• Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells , 2019
• Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center , 2018
• CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation , 2001
• A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma , 2019
• PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma , 2019
• A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome , 2021
• A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome , 2019
• A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. , 2020
• A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT , 2020
• Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience. , 2020
• β-catenin mutations in acute myeloid leukemia , 2020
• β-catenin mutations in acute myeloid leukemia , 2020
• Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk , 2020
• Efficacy and safety of weekly carfilzomib (70 mg/m sup2/sup ), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies/title , 2020
• Efficacy and safety of weekly carfilzomib (70\u2009mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies , 2020
• Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values , 2014
• Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) , 2020
• Insights on Multiple Myeloma Treatment Strategies , 2019
• Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation , 2015
• Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation , 2021
• Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications , 2021
• Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study , 2021
• Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study , 2021
• Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma , 2021
• Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT) , 2021
• Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT) , 2020
• Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis , 2021
• COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network , 2021
• Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma , 2021
• Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group , 2021
• Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide\u2010pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics , 2021
• Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network , 2021
• Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review , 2021
• Health\u2010related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial , 2021
• Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party , 2021
• Expert review on soft\u2010tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations , 2021
• A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT , 2021
• Prognostic impact of early\u2010versus\u2010late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT , 2021
• HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA , 2021
• Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study , 2021
• Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group , 2021
• Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma , 2021
• Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial , 2021
• CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma , 2021
• Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors , 2021
• β-catenin mutations in acute myeloid leukemia , 2020
• Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk , 2020
• Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network , 2020
• β-catenin mutations in acute myeloid leukemia , 2020
• The outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4T cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect , 2018
• Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data , 2020
• Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set , 2020
• Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma , 2012
• Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF , 2000
• High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis , 2007
• A RAPID DRUG SENSITIVITY ASSAY FOR NEOPLASMATIC CELLS , 1988
• Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients , 2012
• HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia , 1997
• Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey , 1998
• Vitiligo after Hematopoietic Cell Transplantation: Six Cases and Review of the Literature , 2008
• Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914) , 2001
• Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk , 2020
• Drug Targeting of Genomic Instability in Multiple Myeloma , 2020
• Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma , 2016
• Isatuximab for the treatment of relapsed/refractory multiple myeloma , 2020
• Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study , 2020
• Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial , 2020
• Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study , 2020
• Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice , 2020
• Prognostic scoring system after transplantation in myeloma: predicting early relapse , 2020
• Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network , 2020
• Drug Targeting of Genomic Instability in Multiple Myeloma , 2020
• A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT , 2020
• Drug Targeting of Genomic Instability in Multiple Myeloma , 2020
• Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma , 2020
• Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma , 2020
• Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation , 2020
• Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study , 2020
• Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS) , 2020
• Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT , 2020
• Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma , 2020
• Our Treatment Approach to Hairy Cell Leukemia , 2020
• The impact of 17 B estradiol level variations on blood lymphocyte counts among healthy females , 2018
• Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience , 2018
• Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies , 2019
• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial , 2019
• PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma , 2019
• Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation , 2014
• Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4. , 2016
• Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia , 1998
• Familial Multiple Myeloma Associated with Disorders of Chronic Inflammation: First Report from Turkey , 2008
• Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) , 2016
• Lack of Prognostic Value of CD34 in Adult AML , 2009
• Hemorrhagic Cystitis as a Complication of Bone Marrow Transplantation , 2013
• The effect of G-CSF on lymphocyte subsets and CD34 cells in allogeneic stem cell transplantation , 2001
• Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. , 2012
• Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM) , 2001
• Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF , 2009
• Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation , 2001
• Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease , 2004
• Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). , 2016
• Expression of IFITM1 in chronic myeloid leukemia patients , 2005
• title Daratumumab plus bortezomib and dexamethasone iversus/i bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR/title , 2018
• Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. , 2016
• Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective , 2011
• The impact of the CD34 cell dose on engraftment in allogeneic peripheral blood stem cell transplantation , 1999
• Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) , 2016
• IMWG consensus on maintenance therapy in multiple myeloma , 2012
• Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up , 2011
• Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective , 2010
• Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial , 2010
• Filgrastim-Mobilized Peripheral Blood Progenitor Cells Versus Bone Marrow Transplantation For Treating Leukemia: 3-Year Results From The EBMT Randomized Trial , 2005
• Hepatitis B virus infection in allogeneic bone marrow transplantation , 1997
• Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial , 2019
• Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
• A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis , 2019
• Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients , 2019
• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019
• Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide and/or Bortezomib Containing Regimens , 2019
• Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 , 2019
• Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice , 2019
• Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma , 2019
• Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival , 2009
• Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow , 2003
• Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience , 2018
• The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females , 2018
• Prenatal diagnosis of organic acidemias at a tertiary center , 2019
• Total Blood Lymphocyte Count Alteration During and after Pregnancy , 2017
• Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies , 2018
• Subsequent malignancies after allogeneic hematopoietic stem cell transplantation , 2017
• KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR? , 2018
• KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR? , 2018
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation , 2018
• Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma , 2017
• Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study , 2017
• Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment , 2017
• Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial , 2011
• CD41 and CD42 hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation , 2001
• An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells , 2011
• Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations , 2010
• Thrombopoietic Cytokines in Patients with Iron Deficiency Anemia with or without Thrombocytosis , 2000
• Kronik Lenfositik Lösemi’de Tanı Anında Hipogammaglobulinemi Sağkalım ve Enfeksiyon Riski Üzerine Etklili Midir? , 2018
• Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement , 2011
• Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. , 2018
• Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group , 2011
• Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group , 2008
• Management of treatment-emergent peripheral neuropathy in multiple myeloma , 2012
• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) , 2011
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials , 2011
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study , 2018
• A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis , 2018
• Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience , 2018
• The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females , 2018
• Extracorporeal photochemotherapy in mycosis fungoides , 2017
• Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies , 2018
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipientss? , 2018
• Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study , 2018
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• Heparin enhances CD34 content of stem cells collected following G-CSF /- chemotherapy , 2017
• Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• The safety of bortezomib for the treatment of multiple myeloma , 2018
• Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network , 2018
• Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel , 2018
• Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia , 2001
• Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells , 2017
• Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients? , 2018
• Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study , 2017
• The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans , 2011
• Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 , 2011
• International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009
• Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and ipost-hoc/i analyses on progression-free survival and tumour growth/title , 2017
• Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival A Quasi Experimental Study , 2016
• Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
• Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
• A single center experience with two decades of follow-up on patients with hairy cell leukemia. , 2017
• Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia. , 2017
• A single center experience with two decades of follow-up on patients with hairy cell leukemia. , 2017
• Large unstained cell percentage as a predictor ofefficacious peripheral stem cell mobilization in autologousstem cell transplantation , 2017
• Evaluating peritransplant albumin decline as a predictor ofacute graft versus host disease , 2017
• Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely? , 2017
• P529HLA C1/C1 homozygosity decreases relapse rate afterallogeneic hematopoietic stem cell transplantation(Allo-HSCT) in acute myeloid leukemia (AML) patients , 2017
• A Biosimiliar G-CSF filgrastim is as effective as a referencedrug however itis not as cost effectiveas it supposed to beand by the way no impact on the health care system , 2017
• Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience , 2017
• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study , 2017
• Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial , 2017
• Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study , 2017
• THE IMPACT OF 17Β ESTRADIOL LEVEL VARIATIONS ON BLOOD LYMPHOCYTE COUNTS AMONG HEALTHY FEMALES , 2017
• Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells , 2012
• Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic? , 2011
• Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials , 2012
• Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma , 2013
• Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study , 2013
• Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease , 2013
• European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014
• High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial , 2014
• Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study , 2014
• Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee , 2014
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial , 2014
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma , 2014
• Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma , 2014
• HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology , 2014
• Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups , 2015
• Effects of in utero cord blood collection on post-cesarean hemoglobin levels , 2015
• Impact of “Killer Immunoglobulin-Like Receptor /Ligand” Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival , 2015
• European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications , 2015
• Insight into human protease activated receptor-1 as anticancer target by molecular modelling , 2015
• Differences between graft product and donor side effects following bone marrow or stem cell donation , 2003
• Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants , 2016
• How to Improve Cord Blood Engraftment , 2016
• Editorial How to Improve Cord Blood Transplantation By Enhancing Cell Counts or Engraftment , 2016
• Flow Cytometrıc Aldehyde Dehydrogenase Aldh Assay Enables A Fast And Accurate Human Umblical Cord Blood Hematopoietic Stem Cell Assessment , 2016
• Phase 2 study of tabalumab a human anti B cell activating factor antibody with bortezomib and dexamethasone in patients with previously treated multiple myeloma , 2016
• extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease , 2017
• Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone the PANORAMA 1 trial a randomised placebo controlled phase 3 trial , 2016
• HLA polymorphism and risk of multiple myeloma , 2016
• Daratumumab Bortezomib and Dexamethasone for Multiple Myeloma , 2016
• Central nervous system involvement by multiple myeloma A multi institutional retrospective study of 172 patients in daily clinical practice , 2016
• Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma outcomes by prior treatment , 2016
• A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker , 2016
• Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial , 2015
• Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma , 2015
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma , 2015
• Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma , 2015
• Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial , 2015
• Antilymphocyte Thymocyte Globulin for the Treatment of Steroid Refractory Acute Graft Versus Host Disease 20 Year Experience at a Single Center , 2015
• Analysis of Final Data from the Multinational Non Interventional Observational Emmos Study NCT01241396 in Patients Pts with Multiple Myeloma MM in Real World Clinical Practice , 2015
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma a multicentre randomised double blind phase 3 trial , 2014
• Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008
• International uniform response criteria for multiple myeloma , 2006
• HLA A B C DR haplotypes linkeage and frequencies observed inAnkara University Turkey a report from Tran , 2005
• Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma , 2012
• Retrospective matched pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma , 2015